2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Gene Therapy, Immunotherapy, Monoclonal Antibody Therapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

2154 Decoupled epigenomic and transcriptomic dynamics in non-malignant plasma cells during myeloma progression

Sihong Li, Nathan Liang2, Parvathi Sudha3, Attaya Suvannasankha, MD4, Travis S Johnson, Ph.D.5
1 Indiana University School of Medicine, Indianapolis, United States
2 Brown University, Providence, United States
3 Indiana University School of Medicine, Indianapolis, United States
4 Indiana University School of Medicine, Indianapolis, United States
5 Indiana University School of Medicine, Indianapolis, United States

INTRODUCTION: The bone marrow microenvironment plays a critical role in multiple myeloma (MM) progression. However, the molecular dynamics of non-malignant plasma cells (NPCs) within this niche remain poorly understood. In this study, we developed a computational pipeline to profile NPCs across distinct disease stages: Smoldering MM (SMM), Newly Diagnosed MM (NDMM), and Relapsed/Refractory MM (RRMM). To mitigate high intra-patient clonal variance and single-cell noise, we applied rigorous quality control thresholds to computationally deplete non-target lineages, isolating a highly purified NPC compartment for downstream analysis.

METHODS: Pseudobulk count matrices were constructed from single-cell RNA and ATAC sequencing data across 49 patient samples (10 SMM, 22 NDMM, and 17 RRMM). Single-cell counts were aggregated to the patient level, and differential expression and accessibility analyses were conducted using negative binomial generalized linear models via DESeq2. For each pairwise comparison, differential features were assessed using the Wald test following strict low-count filtering. This pipeline evaluated transcriptomic and epigenomic alterations driven by disease progression and high-risk cytogenetics (1q-gain). Furthermore, ligand-receptor interactions between NPCs and surrounding immune populations were mapped using CellChat to evaluate dynamic network remodeling.

RESULTS: Integrated multi-omic and interaction analyses revealed a distinct decoupling between NPC epigenomic plasticity and transcriptomic stability, underpinning a progressively complex immune crosstalk network. Across all stages, the NPC transcriptome maintained a rigid terminally differentiated state, exhibiting only localized marker gene shifts (e.g., PDK4 and RSAD2) rather than systemic pathway alterations. However, ATAC-seq demonstrated significant intrinsic epigenomic plasticity in response to microenvironmental stress. In SMM, the NPC communication network was relatively restricted, dominated primarily by stable MHC-I signaling to CD8+ T cells. The transition to active NDMM was marked by increased chromatin accessibility at loci associated with T/NK-cell activation (GZMM, CD5) and leukocyte chemotaxis; this epigenetic priming functionally translated into expanded communication diversity, notably involving MIF and PECAM1 interactions with myeloid populations, and PTPRC-CD22/BAFF signaling with B cells. With further progression to RRMM, NPCs displayed regulatory priming for macrophage migration and interleukin-1 production, which shows a heavily remodeled signaling landscape enriched in immune-regulatory and extracellular matrix-associated pathways (FN1, COLLAGEN). Additionally, stratification by 1q-gain identified targeted functional adaptations within the NPC compartment, indicated by the upregulation of TGFB2 and IL21R, as well as altered cell-recognition programming.

CONCLUSION: Despite lacking detectable copy-number abnormalities, non-malignant plasma cells undergo dynamic adaptations during myeloma progression. While resisting global transcriptomic reprogramming, NPCs utilize targeted epigenomic plasticity to reorganize their chromatin in response to malignant microenvironmental stress. This intrinsic epigenetic remodeling facilitates an increasingly complex web of immune communications: transitioning from limited, targeted signaling in SMM to diverse, inflammatory, and immune-regulatory networks in advanced disease, which are further modulated by localized high-risk 1q-gain niches.

Sihong Li: No relevant conflicts of interest to declare.